Three-year safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Final analysis of an all-case postmarketing surveillance study
Modern Rheumatology · 2025
DOI: 10.1093/mr/roaf017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Masataka Kuwana und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Piperidines, Pyrimidines, Antirheumatic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To evaluate tofacitinib real-world safety/effectiveness in patients with rheumatoid arthritis (RA) in Japan in a 3-year all-case postmarketing surveillance study.
Methods
All patients with RA who initiated tofacitinib (30 July 2013–03 December 2017) were registered in Japan. Serious infections/malignancy/mortality incidences were compared in patients with active RA after >8 mg methotrexate/week for ≥3 months who received tofacitinib or other drugs (control: methotrexate/other disease-modifying antirheumatic drugs/immunosuppressants). Disease activity was assessed over 3 years.
Results
The adherent comparative safety analysis set included 3731/2419 (tofacitinib/control) patients. Baseline (tofacitinib/control) biologic disease-modifying antirheumatic drug history (53.3%/12.2%), methotrexate history (81.4%/98.6%), and RA stage (I–II: 45.3%/67.1%) and class (1–2: 76.5%/90.8%) varied between groups. For tofacitinib vs control, incidence rates [patients with event/100 patient-years (95% confidence interval)] were 6.86 (5.96–7.86) vs 1.42 (0.97–2.00) for serious infections (adjusted hazard ratios 3.25–3.80); 1.40 (1.18–1.66) vs 0.88 (0.66–1.15) for malignancies (adjusted hazard ratios 1.37–1.53); 0.89 (0.72–1.10) vs 0.26 (0.15–0.43) for mortality (unadjusted hazard ratio 3.29). Remission/low disease activity rates with tofacitinib increased over 3 years.
Conclusions
Serious infection rates were higher, and malignancy rates were numerically higher with tofacitinib vs control. Results should be interpreted cautiously due to imbalanced groups and unmeasured confounders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan.
- Inflammation and Immunology, Medical Affairs, Pfizer Japan Inc, Tokyo, Japan.
- Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan.
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
- Department of Paediatrics, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
- Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan.
ORCID-Profile: Masataka Kuwana, Naoto Tamura, Masayoshi Harigai, Nami Okamoto, Ayako Nakajima, Masato Hoshi, Michiaki Takagi, Sakae Tanaka, Yoshiya Tanaka
Zitieren
APA
Kuwana, M., Sugiyama, N., Momohara, S., Atsumi, T., Takei, S., Tamura, N., Harigai, M., Fujii, T., Matsuno, H., Yamamoto, K., Takasaki, Y., Okamoto, N., Takahashi, N., Nakajima, A., Nakajima, A., Tanigawa, M., Endo, Y., Hirano, T., Hoshi, M., …, & Takeuchi, T. (2025). Three-year safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Final analysis of an all-case postmarketing surveillance study. Modern Rheumatology. https://doi.org/10.1093/mr/roaf017
Vancouver
Kuwana M, Sugiyama N, Momohara S, Atsumi T, Takei S, Tamura N, et al. Three-year safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Final analysis of an all-case postmarketing surveillance study. Modern Rheumatology. 2025. doi:10.1093/mr/roaf017
BibTeX
@article{Kuwana2025,
author = {Kuwana, Masataka and Sugiyama, Naonobu and Momohara, Shigeki and Atsumi, Tatsuya and Takei, Syuji and Tamura, Naoto and Harigai, Masayoshi and Fujii, Takao and Matsuno, Hiroaki and Yamamoto, Kazuhiko and Takasaki, Yoshinari and Okamoto, Nami and Takahashi, Nobunori and Nakajima, Atsuo and Nakajima, Ayako and Tanigawa, Miki and Endo, Yutaka and Hirano, Toshitaka and Hoshi, Masato and Mimori, Tsuneyo and Takagi, Michiaki and Tanaka, Sakae and Tanaka, Yoshiya and Takeuchi, Tsutomu},
title = {Three-year safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Final analysis of an all-case postmarketing surveillance study},
journal = {Modern Rheumatology},
year = {2025},
doi = {10.1093/mr/roaf017}
}
EUVIMED